AUSTIN, Texas

,

Sept. 1, 2021

/PRNewswire/ — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in the following medical and investor conferences:

Investor Meetings

• 
  2021 Wells Fargo Virtual Healthcare Conference
  
  ,
  
  September 9
  
• 
  H.C. Wainwright 23
  
  ^rd
  
  Annual Global Investment Conference
  
  ,
  
  September 13
  
• 
  2021 Cantor Virtual Global Healthcare Conference
  
  ,
  
  September 27
  

Medical Conferences

• 
  International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2021)
  
  ,
  
  September 17 – 22
  
• 
  50
  
  ^th
  
  Child Neurology Society (CNS) Annual Meeting
  
  ,
  
  September 29 – October 2
  

At both the MDS Virtual Congress and the CNS Annual Meeting, a poster presentation will outline a subset analysis from the Company

‘

s previously reported Phase 1/2 and Phase 2 open label extension studies of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D). In the poster, analysis of gait kinematics and spasticity was completed using video compilations.

To access live and/or archived Investor Conference webcasts, visit the

Events & Presentations

section of the Company

‘

s website. A replay of Company webcasts is archived on the website for 30 days following presentations.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea’s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company began dosing patients in a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in

June 2021

. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit

Home

.

View original content to download multimedia:

https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-multiple-conferences-in-september-2021-301366671.html

SOURCE Aeglea BioTherapeutics, Inc.